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Progressive macular hypomelanosis (PMH) is a skin condition that normally causes 23 
symmetrically distributed hypopigmented macules on the front and back of the trunk, but 24 
rarely the face. To date, the pathophysiology of the condition is not well understood, but a 25 
role for the anaerobic skin bacterium Cutibacterium (previously Propionibacterium) acnes in 26 
the development of the disease has been proposed due to its sole presence within lesional, 27 
but not normal peri-lesional, skin. The success of antimicrobials in the treatment of PMH also 28 
provides circumstantial evidence that this association may be causal, although this is still to 29 
be proven. More recent culture and metagenomic typing studies indicate that strains of C. 30 
acnes subsp. elongatum (type III) may be important in the aetiology of the condition, which 31 
would help to explain why PMH does not normally affect the face since such strains are rarely 32 
present there, and why no association between this condition and acne vulgaris is found; 33 
acne appears to primarily involve type IA1 strains from C. acnes subsp. acnes (type I). In this 34 
review we summarise current knowledge on the relationship between C. acnes and PMH, and 35 
re-examine previous challenges to the view that the bacterium plays a role in the condition 36 
against the backdrop of newly emerged data.    37 
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1. Introduction 38 
Progressive macular hypomelanosis (PMH) is a relatively uncommon dermatosis usually 39 
characterised by ill-defined nummular, non-scaly and symmetric hypopigmented macules 40 
that form predominantly on the front and back of the trunk, and without prior history of skin 41 
injury, infection or inflammation (Fig. 1); these macules can be discrete or display confluence 42 
when found in and around the midline1. Like the very common skin condition acne vulgaris, 43 
PMH normally affects adolescents and young adults where its cosmetic effects may have 44 
social and psychological impacts1,2,3. The disorder rarely affects the proximal extremities and 45 
the skin of the face, which has been a key clinical feature1,3. PMH is found worldwide and 46 
affects different Fitzpatrick skin types as well as both sexes, but the disorder does appear to 47 
be much more prevalent in females1,4-7. PMH is often misdiagnosed as the fungal infection 48 
pityriasis versicolor, pityriasis alba or post-inflammatory hypopigmentation, and can remain 49 
stable, progress slowly over a long time period or, in some cases, spontaneously disappear 50 
after mid-life1,3,4,8. While the exact incidence of PMH within different populations is unclear, it 51 
is likely to be an under-reported disorder as some cases may be misdiagnosed and not all 52 
patients, particularly males, will see a clinician for treatment6. In this review, we evaluate the 53 
strength of current evidence supporting a pathogenic role for the anaerobic bacterium 54 
Cutibacterium acnes (previously Propionibacterium acnes) in the aetiology of PMH, 55 
particularly in light of recent culture and metagenomic typing studies, and investigation of 56 
porphyrin production by different strains of the bacterium.  57 
2. Histological and electron microscopic features 58 
Histologically, PMH does not appear to be associated with any significant abnormalities of 59 
the dermis apart from a decrease in epidermal pigment, but a mild perifollicular infiltrate of 60 
lymphocytes has been observed in some, but by no means all, lesional skin samples2,4,6-10. 61 
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Detailed ultrastructural studies have provided evidence that PMH results from altered 62 
melanogenesis, leading to reduced pigmentation, and changes in melanosome size, 63 
aggregation, maturation and distribution2,3,6,8-9,11-12. Furthermore, it does not appear that 64 
defects in melanosome degradation play a role in the pathophysiology of PMH as there is no 65 
evidence for disintegrated melanosomes in the lysosomal compartments of PMH lesions12. 66 
3. Evidence supporting a potential role for Cutibacterium acnes in the aetiology of PMH 67 
While the underlying cause of PMH is still not clear, a pathogenic role for the Gram-68 
positive, anaerobic bacterium C. acnes in the aetiology of the condition has been proposed, 69 
possibly via the production of a depigmenting factor or an agent that interferes with 70 
melanogenesis4,5. C. acnes is part of the normal human microbiota and found predominately 71 
on the skin and muscosal surfaces. The organism is an opportunistic pathogen most noted for 72 
its association with acne vulgaris13, but has now also been linked to other human infections 73 
and conditions, including medical device and soft tissue infections14,15, cervical disc disease16, 74 
prostate cancer17 and sarcoidosis18.  75 
3.1 Culture and non-culture-based detection 76 
Bacterial culture has demonstrated the sole presence and accumulation of C. acnes in 77 
biopsy samples of PMH lesions, but not biopsies of adjacent non-lesional skin from the same 78 
patient4,5 (Table 1). Furthermore, 16S rRNA-based quantitative real-time PCR detection of C. 79 
acnes has found a significantly greater incidence of the bacterium in lesional versus adjacent 80 
non-lesion skin of patients in respect to genome copy number, consistent with culture results 81 
and indicating enrichment in lesions5; in the latter case we can speculate that this may reflect 82 
localised perturbations in the skin environment that stimulate overgrowth. The presence of C. 83 
acnes within hypopigmented lesions from patients with PMH, but not normal pigmented skin 84 
from the trunk of the same patient, can also be observed upon Gram-staining, revealing 85 
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Gram-positive rods with a high population density1,4,9. Furthermore, upon examination of the 86 
skin in a dark room with UV radiation from a Wood’s lamp, a puntiform orange-red follicular 87 
fluorescence within hypopigmented spots is observed due to the presence of porphyrins 88 
produced by the bacterium, such as coproporhyrin III; this fluorescence is absent in peri-89 
lesional normal skin1,4,7,10,12. Interestingly, while this characteristic florescence of PMH lesions 90 
upon Wood’s lamp examination has been described in many studies, it has not been observed 91 
in all (see section 5.1).  92 
3.2 Therapeutic success of antimicrobial-based treatments 93 
Treatments for PMH based on topical corticosteroids and topical or systemic antifungals 94 
have not proved efficacious, but re-pigmentation of the skin can be achieved using ultraviolet 95 
light A (UVA) or narrow-band UVB (NB-UVB)-based treatments, either as a monotherapy or in 96 
combination with topical or oral antimicrobials1,6,9,10,19-24. Such UV treatments are believed to 97 
work by stimulating melanogenesis and, potentially, inhibition of C. acnes in the case of NB-98 
UVB (see section 5.3), but the results appear variable and in many cases are only temporary 99 
leading to recurrence of the condition6,20,21,24.  100 
In a within-patient, left-right trunk comparison study, Relyeld et al.25 demonstrated that 101 
topical treatment with 5% benzoyl peroxide (BPO) (morning) and 1% clindamycin hydrogel 102 
(night-time) in combination with UVA radiation (antibacterial therapy arm) was much 103 
superior for re-pigmentation versus 0.05% fluticasone and UVA treatment only (anti-104 
inflammatory therapy arm). This appeared, therefore, to exclude the possibility that 105 
treatment success was due solely to UVA treatment, and provided evidence to support a 106 
bacterial role, such as C. acnes, in the pathophysiology of PMH. Furthermore, upon a 3-month 107 
follow-up, PMH patients were still found to have retained their re-pigmentation, although 108 
information on whether this persisted is not available. Since then, there have been many 109 
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studies investigating the effectiveness of treatments for PMH using topical antibiotic lotions 110 
and BPO hydrogels (in combination or separately) alongside narrow-band UVB (NB-UVB) 111 
treatment6,9,19,21,23. Treatment success for PMH has also been achieved using the oral 112 
tetracycline derivatives doxycycline, minocycline and lymecycline, used in the management of 113 
acne, either with or without BPO26-29; this provides further circumstantial evidence that C. 114 
acnes may contribute to the development of PMH. In particular, treatment of PMH with a 115 
combination of oral lymecycline (300 mg/d) and topical 5% BPO was very successful leading 116 
to repigmentation and maintenance during a 6-to-12 month follow-up period28,29. Attempts 117 
to treat PMH using oral isotretinoin have also been described in the literature, but the results 118 
obtained have been variable30-31.  119 
4. The hunt for a novel Cutibacterium species associated with PMH 120 
A conundrum in the proposal that C. acnes is the cause of PMH has been why the disorder, 121 
unlike acne, rarely affects the face where levels of the bacterium are at their highest, and why 122 
acne does not predispose individuals to PMH development. This led Relyveld et al.32 to 123 
propose that the organism potentially causing PMH may not actually be C. acnes, but a closely 124 
related Cutibacterium species indistinguishable by conventional phenotypic/ biochemical 125 
methods.  126 
4.1 Amplified Fragment Length Polymorphism and 16SrRNA gene analysis  127 
Genetic analysis of skin biopsy-associated bacterial isolates collected from patients with 128 
PMH and patients with acne by Amplified Fragment Length Polymorphism (AFLP) typing 129 
identified three major genetic clusters that differed in their distribution between the two 130 
conditions (p<0.01; Freeman-Halton extension of Fisher’s extact test) (Table 2)32. Of note was 131 
the observation that isolates from DNA group 3, in contrast to the other DNA groups, were 132 
only associated with PMH, but never acne (Fishers exact test; p<0.01), and analysis of 133 
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multiple bacterial colonies isolated from acne and PMH samples did not demonstrate the 134 
presence of mixed AFLP types. 16S rRNA gene sequencing revealed very high sequence 135 
identities between all clusters, with only a single nucleotide polymorphism (SNP) at position 136 
827 separating DNA groups I and II32, which is a characteristic difference between the well 137 
described C. acnes type I (C. acnes subsp. acnes) and type II (C. acnes subsp. defendens) 138 
phylotypes33, while group 3 isolates differed from group 1 due to a SNP at position 1243 139 
(G1243A). While biochemical analysis with the rapid ID 32A multi-test identification system 140 
confirmed DNA groups 1 and 2 as C. acnes (99.9% certainty), isolates from DNA group 3 gave 141 
ambiguous results and could not be identified phenotypically despite the molecular results 142 
indicating a unique C. acnes cluster; 16S rRNA identity is not, however, always a guarantee of 143 
species identity, especially in the case of a recently diverged and very closely related sister 144 
taxon34. This led to the proposal that organisms from DNA group 3 may represent a novel and 145 
very closely related bacterium from the genus Cutibacterium32.  146 
4.2 PCR phylotyping and single- and multi-locus sequence type analysis  147 
At the time of the original AFLP study of Relyveld et al.32, knowledge on the intraspecies 148 
diversity of C. acnes was only developing, as were the molecular methods for more detailed 149 
population genetic analysis of the bacterium. Today, our appreciation of C. acnes at the 150 
interspecies level is much more complete (Table 3), and specific molecular typing tools for the 151 
bacterium, particularly multiplex-PCR phylotyping, high-resolution single and multilocus 152 
sequence typing (HR-SLST and MLST, respectively) and ribotyping35-39, have also been 153 
established enabling researchers to deeper explore the association of specific lineages with 154 
skin health and disease. 155 
Against this new landscape of understanding, and utilising the improved typing methods 156 
now available, Barnard et al.40 conducted a population genetic analysis of C. acnes isolates 157 
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recovered from the lesional skin of patients with PMH. They demonstrated a strong statistical 158 
association between strains from the more recently described type III phylogenetic lineage 159 
(now known as C. acnes subsp. elongatum41,42) and lesions, but not those representing other 160 
phylogenetic groups, including those associated with acne (type IA1). Strikingly, in silico 16S 161 
rDNA SNP analysis revealed that the isolates from AFLP DNA group 3 (G1243A) previously 162 
described in association with PMH were also consistent with the type III lineage (Fig. 2). 163 
Furthermore, analysis of the biochemical phenotype of three representative type III strains 164 
from PMH lesions using the Rapid ID 32A multi-tests identification system failed to correctly 165 
identify the isolates as C. acnes, consistent with the previous results obtained for AFLP DNA 166 
group 3 strains32.  167 
A subsequent study by Peterson et al.29 based on HR-SLST metagenomic analysis of skin 168 
surface swabs taken from 24 PMH back lesions and adjacent non-lesional skin regions of eight 169 
female patients, confirmed the association of type III strains with PMH. Interestingly, 170 
treatment of patients using a combination of lymecycline (300 mg/d) and 5% BPO led to a 171 
reduced proportion of type III within patients’ samples, and a parallel reduction or 172 
disappearance of their PMH lesions. In patients whose type III population was almost totally 173 
eliminated there was almost no lesions remaining and the type distribution after treatment 174 
generally reverted to that of controls (Fig. 1). Investigation of eight healthy female volunteers 175 
also found that type III strains were more common on the back, especially the lower back, but 176 
normally not present on the forehead or buccal mucosa; one patient was, however, found to 177 
have a significant proportion of type III strains on their forehead despite, presumably, no 178 
PMH lesions at this site (presence or absence of facial PMH was not definitely stated for this 179 
patient). Unlike previous studies, a relatively high proportion of type III isolates was also 180 
found on non-lesional skin, but this may have reflected issues around clear differentiation 181 
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between lesional and non-lesional sites using skin swab sampling as opposed to skin biopsy. 182 
5. Challenges to the proposal that C. acnes is involved in the aetiology of PMH 183 
5.1 PMH in the apparent absence of lesional C. acnes 184 
 Despite independent studies highlighting a strong association of C. acnes with PMH, a 185 
number of cases where C. acnes appears absent in lesional skin, as judged by Wood’s lamp 186 
examination, histological staining and, in some cases, microbiological culture from skin swabs 187 
or biopsies have been reported6,8,43-44. It is important, however, to note that a negative 188 
Wood’s lamp result does not confirm that C. acnes is absent, only that levels are below the 189 
density detection limit (~103 organisms)45. Furthermore, a recent investigation found that 190 
type II and III strains produce very low levels of porphyrin compared with type I organisms, 191 
and that cultures of type II and III strains on solid media do not fluoresce upon Wood’s lamp 192 
illumination46. This indicates that lesions dominantly or solely colonised with type III strains 193 
may not have detectable follicular fluorescence. It also highlights that PMH lesions normally 194 
appear to have a mixed phylotype composition containing at least fluorescent type I strains, 195 
as well as type III in the majority of instances. The absence of mixed types and the detection 196 
of mostly type III strains based on previously described culture-based studies of lesional skin 197 
biopsies may, therefore, reflect the differential growth of dominant clones of this subspecies 198 
present in high numbers.  199 
5.2 Rare occurrence of PMH on the face where C. acnes type III are normally absent.  200 
A lack of facial involvement in PMH, despite high concentrations of C. acnes at this site, 201 
has been one of the biggest challenges to the view the bacterium has a role in the 202 
development of this condition. The observation of an association between C. acnes type III 203 
strains and PMH does, however, help to explain, at least in part, this intriguing clinical feature 204 
of the disease since type III strains normally appear to be absent or found in very low 205 
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abundance on the face of most individuals38. While a recent study reporting four adult cases 206 
with apparent facial PMH, in addition to trunk, arm and leg lesions, appears inconsistent with 207 
this view, no microbiological analysis was described for these patients47. As a result, 208 
conclusions regarding the potential role of the bacterium in these specific facial cases of PMH 209 
cannot be completely dismissed. It was interesting to note that the patients were much older 210 
(40-65 years) than normally seen and it is currently unclear how the distribution of C. acnes 211 
phylogroups and specific strain types on the skin may modify as we age; we can speculate 212 
that in some older individuals type III strains may become more abundant on the face due to 213 
age-related changes in cutaneous physiology that influence bacterial diversity. The previous 214 
observation of a PMH patient with significant levels of type III on their forehead does 215 
highlight that, while uncommon, the bacterium can indeed be present on the face of some 216 
individuals29 (section 4.2). However, the presumed presence of only truncal lesions on this 217 
patient does complicate the view that a lack of facial PMH is solely down to the absence of 218 
type III organisms at this skin site. Other factors, including the nature of the strain type(s) 219 
present, their abundance and interaction with other microbiota, may well be important 220 
factors, alongside host response and other variables. 221 
5.3 Antibacterial therapy versus phototherapy 222 
A number of studies have challenged the original findings of Relyeld et al.25 in regards to 223 
the effectiveness of antimicrobial treatment and phototherapy versus phototherapy alone. In 224 
particular, Sim et al.21 and Selim et al.6 did not find any significant difference in 225 
repigmentation of PMH lesions using daily topical 5% BPO and 1% clindamycin antimicrobial 226 
treatments with NB-UVB versus NB-UVB monotherapy. Furthermore, in many cases 227 
recurrence of the condition occurred, although some patients retained a degree of clinical 228 
improvement.  While such observations question the pathogenic role for C. acnes in PMH, a 229 
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key difference between these studies and that of Relyeld et al.25 relates to the use of NB-UVB 230 
rather than UVA plus psoralen (PUVA). NB-UVB has been shown, in vitro, to have antibacterial 231 
effects on cutibacteria which is not observed with UVA, potentially explaining the 232 
contradictory results48,49. It is interesting to note, however, that in the study of Selim et al.6 233 
only two PMH patients had hypopigmented lesions that demonstrated fluorescence under a 234 
Wood’s lamp indicating absent or low levels of C. acnes, or colonization with low porphyrin-235 
producing strains, while data from Sim et al.21 in relation to Wood’s lamp analysis was not 236 
described. In contrast, Hassan et al.9 found that topical (2% erythromycin lotion) and systemic 237 
(100 mg doxycycline b.i.d) antimicrobial treatments alongside NB-UVB for 3 months did give 238 
superior results compared to NB-UVB alone, and with no relapse in a 6 month follow up 239 
period. 240 
6. Future research.  241 
Additional studies are clearly needed to further dissect the underlying biological 242 
mechanisms driving the development of PMH. To date, our understanding of the underlying 243 
biology of type III strains and their interaction with other microbiota, alongside their niche 244 
requirements and capacity to cause disease, remains unclear, but an inflammatory phenotype 245 
has been observed, as well as the presence and absence of unique genomic elements when 246 
compared to other phylotypes40,50. It will be important to determine whether C. acnes, and 247 
particularly type III strains, have the capacity to interfere with melanogenesis via a 248 
depigmenting factor(s) or stimulation of a specific host response; initially, this could be 249 
achieved using appropriate in vitro cell culture models to study host-interacting properties. It 250 
is also interesting that some patients confuse PMH with leprosy, a chronic granulomatous 251 
disease caused by another intracellular bacterium, Mycobacterium leprae1. In particular, the 252 
tuberculoid from of the disease is characterised by a very small number of scaly, well defined 253 
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hypopigmented macules of varying symmetry on the skin, although poorly defined macules 254 
with mild hypopigmentation and erythema are also present in lepromatous forms51. Previous 255 
work has suggested this reflects marked reductions in the number of normal melanocytes in 256 
the lesions and the presence of atrophic melanocytes with reduced activity, while other 257 
studies suggest it may reflect defective transfer of melanosomes from melanocytes to 258 
keratinocytes52,53. In the tuberculoid form of the condition, acid-fast bacilli are rarely found, 259 
which may be a relevant observation when considering PMH lesions in the apparent absence 260 
of C. acnes (see section 5.1). While hypomelanosis disorders can also be caused by other 261 
types of microorganisms, such as fungi and yeasts, hypopigmentation in leprosy appears 262 
more noteworthy in the context of PMH given that mycobacteria and cutibacteria are 263 
distantly related actinomycetes, and have also been linked to another granulomatous 264 
disease, sarcoidosis54. While highly speculative, it may be that the hypopigmentation 265 
observed in both conditions is driven by some shared or similar characteristic of these 266 
bacteria (secretory or host-response). Previous studies on leprosy pathogenesis may, 267 
therefore, have informative aspects for researchers interested in future PMH studies, despite 268 
the many obvious differences between the two diseases.    269 
The observation of PMH in twins, along with our current understanding of the 270 
epidemiology of the condition, also hints at a multifactorial inheritance aetiology driven by 271 
both genetics and environmental factors that may include specific strains of C. acnes and 272 
hormonal influences given its apparent increased rate in females and description of an 273 
acceleration of hypopigmentation in one patient after pregnancy8. The penetrance of PMH is, 274 
therefore, likely to be an interplay of these different influences, and further studies of genetic 275 
factors that may influence development of the disease and its clinical course should also be 276 
an important area of focus. We also need to better understand the pathophysiology of those 277 
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rare cases where PMH involves the face, as well as any differences that occur in the 278 
development of the condition in the presence and apparent absence of lesional C. acnes. 279 
7. Conclusion 280 
While a number of independent studies have found a strong association between C. acnes 281 
type III and PMH, a definite causal role is still to be determined. Nevertheless, the 282 
demonstration that type III strains are associated with the condition does help to explain, at 283 
least partly, the observations that PMH does not normally affect the face, nor is linked to the 284 
development of acne. Although reports of PMH in the apparent absence of C. acnes do 285 
complicate our understanding of the bacterium’s role in the disease, further studies are 286 
required to definitely confirm this. It may be that C. acnes is only one of a number of different 287 
factors that can influence the development of PMH or that, in some instances, the bacterium 288 
initiates a biological response that leads to hypopigmentation, even after it becomes no 289 
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Table 1. Key studies demonstrating an association between C. acnes and PMH 429 





aMale:Female ratio 435 
bStatistical analysis was performed using McNemars test. 436 
   Lesional skin Non-lesional skin  
Study M:Fa Biopsy  + - + - p-valueb 
Westerhof et al.  0:8 2 mm 7 1 1 7 0.04 
Cavalcanti et al.  9:27 4 mm 33 2 4 31 <0.001 
Total 9:35 - 40 3 5 38 <0.0001 
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aData taken from the study of Relyveld et al.32 447 
bp<0.01 (Freeman-Halton extension of Fisher’s extact test) for differences 448 
between acne and PMH in regards to DNA group distribution.   449 
 AFLP analysisa  
Disorder DNA group 1 DNA group 2 DNA group 3 Total 
Acne 9 2 0 11 
PMH 6 0 8 14 



















aAFLP group from the study of Relyveld et al.32 466 
bCC= clonal complex (https://pubmlst.org/cacnes/) 467 
cRibotypes based on the study of Fitz-Gibbon et al.38 468 
d IA1 = CC1 and CC3; IB = CC4.   469 




 MLST8 CCb Ribotypesc 
IA1 acnes 1 IA1/IBd  CC1; CC3; CC4 RT1; RT5; RT532 
IA2 acnes 1 IB  CC2 RT3; RT16 
IB acnes 1 IB  CC5 RT1 
IC acnes 1 IC  CC107 RT5 
II defendens 2 II  CC6; CC30; CC71, CC72 RT2; RT6 
III elongatum 3 III  CC77 RT9 
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FIGURE LEGENDS: 470 
 471 
Figure 1. Clinical responses of PMH lesions to antimicrobial treatment. Lesional skin 472 
on the back of two patients before (a and c) and after (b and d) daily treatment with 473 
lymecycline (300 mg/d) and BPO washes for 3 months. Figure and modified legend are 474 
from Petersen et al29.  475 
 476 
Figure 2. Alignment of the 16S rDNA sequence from strain ATCC6919 (type IA1), 477 
KPA171202 (type IB) and NCTC10390 (type II) versus type III isolates. The 16S rDNA G>A 478 
SNP described by Relyveld et al.32 as a genetic marker of AFLP DNA group 3 strains is 479 
highlighted. This SNP was present in eight of the 10 type III isolates analysed, but absent in 480 
type strains from the other major C. acnes lineages. Figure and modified legend are from 481 
Barnard et al.40  482 
